Home › Funds › Tetragon Partners GP Ltd › KPTI
Tetragon Partners GP Ltd position in KPTI
KARYOPHARM THERAPEUTICS INC · Health Care
Tetragon Partners GP Ltd reported holding 250,300 shares of KPTI (KARYOPHARM THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.4M, representing 0.40% of its reported portfolio and ranking #30 among its reported holdings. Tetragon Partners GP Ltd has disclosed KPTI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Tetragon Partners GP Ltd's KPTI position evolved
Tetragon Partners GP Ltd first disclosed a stake in KPTI in Q1 2026 at 50,000 shares (US$278K). The position peaked in Q2 2026 at 250,300 shares, worth US$2.4M. Across 2 filings, Tetragon Partners GP Ltd increased the stake 1 time(s), trimmed it 0 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 250,300 shares valued at US$2.4M — an increase of 200,300 shares quarter over quarter.. Notable position changes include a 401% increase in Q2 2026 (shares fell 88% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 50.00K | $278.50K | New |
| Q2 2026 | 250.30K | $2.45M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About KPTI and 13F data
KPTI (KARYOPHARM THERAPEUTICS INC) is a Health Care company. 35 other funds we track also report a position in KPTI — the largest reported positions include ACORN CAPITAL ADVISORS, LLC (US$14.8M), Catalio Capital Management, LP (US$9.2M), Avidity Partners Management LP (US$9.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding KPTI
- ACORN CAPITAL ADVISORS, LLC 1.52M sh · $14.83M · Q2 2026
- Catalio Capital Management, LP 940.86K sh · $9.19M · Q2 2026
- Avidity Partners Management LP 924.49K sh · $9.03M · Q2 2026
- Kalehua Capital Management LLC 685.64K sh · $6.70M · Q2 2026
- NEA Management Company, LLC 576.78K sh · $5.64M · Q2 2026
More on Tetragon Partners GP Ltd
FAQ
How long has Tetragon Partners GP Ltd held KPTI?
Tetragon Partners GP Ltd has disclosed KPTI holdings in 2 of the last 2 reported quarters, going back to Q1 2026.
What is Tetragon Partners GP Ltd's current position in KPTI?
As of Q2 2026, Tetragon Partners GP Ltd holds 250.30K shares of KPTI (KARYOPHARM THERAPEUTICS INC), valued at $2.45M, representing 0.40% of its reported portfolio and ranking #30.
Has Tetragon Partners GP Ltd been buying or selling KPTI?
In the latest 13F filing (Q2 2026), Tetragon Partners GP Ltd increased its position in KPTI. The position peaked in Q2 2026 at 250.30K shares.
Which other funds hold KPTI?
Other major institutional holders of KPTI include ACORN CAPITAL ADVISORS, LLC, Catalio Capital Management, LP, Avidity Partners Management LP, among 35 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.